ANI Pharmaceuticals, Inc. beat EPS estimates 94% of the time across 16 reported quarters (15 beats, 1 misses), averaging +33.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $1.67 | $1.82 | +9.0% | Beat | |
| Q1 FY26 | $0.96 | $1.68 | +75.0% | Beat | |
| Q4 FY25 | $1.62 | $1.98 | +22.2% | Beat | Q4 FY25 call |
| Q3 FY25 | $1.37 | $1.64 | +19.7% | Beat | |
| Q2 FY25 | $1.02 | $1.38 | +35.3% | Beat | Q2 FY25 call |
| Q1 FY25 | $1.09 | $1.37 | +25.7% | Beat | |
| Q4 FY24 | $1.14 | $1.35 | +18.4% | Beat | |
| Q3 FY24 | $0.76 | $1.04 | +36.8% | Beat | |
| Q2 FY24 | $0.64 | $0.72 | +12.5% | Beat | |
| Q1 FY24 | $0.79 | $0.95 | +20.3% | Beat | |
| Q4 FY23 | $0.58 | $0.78 | +34.5% | Beat | |
| Q3 FY23 | $0.57 | $1.05 | +84.2% | Beat |
Back to ANIP overview · ANIP holders · ANIP KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.